The U.K. experience with human lymphoblastoid interferon in HCL: a report of the first 50 cases.
The results of treatment of the first 50 patients with hairy cell leukemia given human lymphoblastoid alpha-interferon (Wellferon) are presented. All patients, irrespective of previous splenectomy or splenomegaly showed evidence of response. Side effects were minor. Surface marker studies provided no clear indication of the mechanism of action of alpha-interferon. It is concluded that Wellferon is highly effective in this disease.
Worman
C P
CP
Department of Hematology, University College Hospital, London, U.K.
Catovsky
D
D
Cawley
J C
JC
Bevan
P C
PC
Bottomley
J M
JM
Nethersell
A B
AB
D000328:Adult; D000368:Aged; D000943:Antigens, Differentiation / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D000954:Antigens, Surface / Q000032:analysis; D004334:Drug Administration Schedule; D005260:Female; D006410:Hematopoiesis; D006801:Humans; D007370:Interferon Type I / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D007943:Leukemia, Hairy Cell / Q000503:physiopathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D013997:Time Factors
D000943:Antigens, Differentiation; D000951:Antigens, Neoplasm; D000954:Antigens, Surface; D007370:Interferon Type I